Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents

Journal of Ovarian Research

Toru Sugiyama¹  Akira Kurose³  Takashi Sawai²  Seisuke Kumagai¹  Tadahiro Shoji¹  Eriko Takatori¹ 

[1] Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1, Uchimaru, Morioka, Iwate, 020-8505, Japan;Department of Pathology, Iwate Medical University School of Medicine, Uchimaru, Morioka, Iwate, 020-8505, Japan;Department of Anatomic Pathology, Hirosaki University Graduate School of Medicine, 5, Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan

关键词: Chemotherapy;    Apoptosis;    DNA damage;    Ovarian cancer;    Clear cell carcinoma;    γH2AX;   

Others  :  815098
DOI  :  10.1186/1757-2215-5-16

 received in 2012-04-20, accepted in 2012-06-12,  发布年份 2012

【 摘 要 】

Objectives

Differences in the incidences and types of DNA damage induced by antitumor agents for clear cell carcinoma (CCC) were determined in 2 ovarian CCC cell lines using γH2AX.

Material and methods

The antitumor activity of anticancer agents, CDDP, CBDCA, PTX and SN-38, was examined using ovarian clear cell carcinoma cultured cell lines (OVISE and RMG-I). After culture, each cell line was treated with each anticancer agent, the cells were collected, fixed, and then reacted with the anti-γH2AX antibody. γH2AX and nuclear DNA were then simultaneously detected by flow cytometry using FITC and propidium iodide, respectively, to determine γH2AX in each cell cycle phase.

Results

After administration of CDDP, DNA damage was frequent in S-phase cells, while cell-cycle arrest occurred in the G1 and G2/M phases and γH2AX did not increase in CDDP-resistant cells. Sensitivities to CDDP and CBDCA differed between the two cell lines. The antitumor effect of PTX is induced by G2/M arrest, and combination treatment with CBDCA, inducing DNA damage in G2/M-phase cells, might be effective.

Conclusions

This is the first study in Japan to evaluate the antitumor activity of anticancer agents by focusing on the relationship between the cell cycle and DNA damage using γH2AX as an indicator. The immunocytochemical method used in this study detects γH2AX, which indicates DNA damage even at very low concentrations and with high sensitivity. Therefore, a promising method of easily and rapidly identifying agents potentially effective against CCC.

【 授权许可】

   
2012 Takatori et al.;licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary. Cancer 2000, 88:2584-2589.
• [2]McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
• [3]Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200.
• [4]Sugiyama T, Fujiwara K: Clear cell carcinoma of the ovary. In American Society of Clinical Oncology 2007 educational book. Edited by Govindan R. , Alexandria, VA; 2007:318-322.
• [5]Takano M, Kikuchi Y, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T: Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep 2006, 16:1301-1306.
• [6]Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y: Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol 2007, 12:256-260.
• [7]Nishino K, Aoki Y, Amikura T, Obata H, Sekine M, Yahata T, Fujita K, Tanaka K: Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol 2005, 97:893-897.
• [8]Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM: H2AX: functional roles and potential applications. Chromosoma 2009, 118:683-692.
• [9]Fragkos M, Jurvansuu J, Beard P: H2AX is required cell cycle arrest via the p53/p21 pathway. Mol Cell Biol 2009, 29:2828-2840.
• [10]Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, Pommier Y: γH2AX and cancer. Nat Rev Cancer 2008, 8:957-967.
• [11]Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, Kanamori Y, Terakawa N: Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002, 93:723-728.
• [12]Zwelling LA, Kohn KW: Mechanism of action of cis-Dichlorodiammineplatinum (II). Cancer Treat Rep 1979, 63:1439-1444.
• [13]Okuma Y, Kiguchi K, Koshitaka Y, Okamura A, Ishiwata I, Kondo H, Ishizuka B, Tadokoro M: Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines. Hum Cell 2003, 16:131-139.
• [14]Rowinsky EK, Donehower RC, Jones RJ, Tucker RW: Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 1988, 48:4093-4100.
• [15]Takahashi M, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Kamazawa S, Sato S, Akeshima R, Terakawa N: Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. Eur J Cancer 2000, 36:1863-1868.
• [16]Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, Hung MH, Liu FS: p53 mutation is infreq1uent in clear cell carcinoma of the ovary. Gynecol Oncol 2001, 80:189-193.
• [17]Enomoto T, Kuragaki C, Yamasaki M, Sugita N, Otsuki Y, Ikegami H, Matsuzaki M, Yamada T, Wakimoto A, Murata Y: Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 2003, 22:447(#1797).
• [18]Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, K Noda, Japanese Gynecologic Oncology Group: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer : a phase 3, open-label, randomized controlled trial. Lancet 2009, 374:1331-1338.
• [19]Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, Potmesil M: DNA topoisomerase-I mediate DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989, 49:4385-4389.